Explorer la conception de médicaments par IA, la pharmacologie computationnelle et la biologie programmable.
Modèles génératifs, AlphaFold et apprentissage automatique accélérant la découverte moléculaire.
FEP, dynamique moléculaire, calcul quantique et cryo-EM dans l'optimisation des candidats.
PROTAC, protéines programmables, promédicaments et ADC de nouvelle génération.
Cadres FDA-EMA, analyse de marché et économie de la découverte de médicaments par IA.
A comprehensive analysis of how generative AI models are transforming de novo molecular design, with the latest methods, tools, and clinical implications.
How DeepMind's AlphaFold 3 is revolutionizing structure-based drug design through protein-ligand complex prediction.
Exploring how AI platforms like PandaOmics identify novel drug targets and accelerate their journey to clinical trials.
A comprehensive guide to ML-based ADMET prediction methods, tools, and their role in reducing late-stage drug failures.
A detailed case study of rentosertib (INS018_055), the first AI-designed drug to reach Phase III clinical trials.
An in-depth analysis of FEP methods for predicting binding free energies and their transformative role in lead optimization.